Prostate Cancer Clinical Trial

Green Tea Extract and Prostate Cancer

Summary

The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression.

View Full Description

Full Description

To evaluate the short-term effects of a daily dose of Polyphenon E administered during the interval between prostate biopsy and radical prostatectomy in men with recently diagnosed prostate cancer. Endpoints will be changes in serum and tissue biomarkers related to progression of cancer.

The effect of Polyphenon E on tumor cell c-Met expression and phosphorylation is the primary objective. Secondary objectives include the effects on the other tissue and serum biomarkers. Evaluation of the safety and tolerability of Polyphenon E in this subject population is another objective.

1.1 Determine the effects of Polyphenon E on tumor cell c-Met expression and phosphorylation levels in patients with prostate cancer 1.2 Determine the effects of Polyphenon E on PI-3K activation in patients with prostate cancer 1.3 Determine the effects of Polyphenon E on MAPK activation in patients with prostate cancer 1.4 Determine the effects of Polyphenon E on expression levels of other proteins involved in motility and invasion such as Rho GTPases and extracellular proteinases in patients with prostate cancer 1.5 Determine the effects of Polyphenon E on markers of angiogenesis in patients with prostate cancer 1.6 Determine the effects of Polyphenon E on serum Prostate Specific Antigen (PSA) in patients with prostate cancer 1.7 Determine the effects of Polyphenon E on other serum markers: C-reactive protein (CRP), Insulin-Like Growth factor I (IGF-I), Insulin-like Growth Factor Binding Protein 3 (IGFBP-3), Hepatocyte Growth Factor HGF 1.8 Evaluate the safety and tolerability of Polyphenon E in this subject population

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

recent biopsy positive for prostate cancer
scheduled for prostatectomy
must be able to swallow capsules
Palpable mass by digital rectal examination (DRE)
Ability to give informed consent and willingness to adhere to study protocol
Age ≥ 18 years and less than 75

Exclusion Criteria:

abnormal liver function
Prior hormonal or surgical therapy for prostate cancer
Liver or kidney problems that would interfere with metabolism of study drug
Any condition that would hamper informed consent or ability to comply with study protocol
Participation in another research study in the last three months
Known malignancy at any site other than prostate
Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

33

Study ID:

NCT00676780

Recruitment Status:

Completed

Sponsor:

Louisiana State University Health Sciences Center Shreveport

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

LSU Health Sciences Center
Shreveport Louisiana, 71103, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

33

Study ID:

NCT00676780

Recruitment Status:

Completed

Sponsor:


Louisiana State University Health Sciences Center Shreveport

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider